Revvity (NYSE:RVTY) Issues FY 2025 Earnings Guidance

Revvity (NYSE:RVTY) issued an update on its FY 2025 earnings guidance on Monday morning. The company provided EPS guidance of 4.900-5.000 for the period, compared to the consensus EPS estimate of 4.940. The company issued revenue guidance of $2.8 billion-$2.9 billion, compared to the consensus revenue estimate of $2.8 billion.

Wall Street Analysts Forecast Growth

Several equities analysts have recently issued reports on the stock. Wells Fargo & Company cut their price objective on shares of Revvity from $130.00 to $102.00 and set an “equal weight” rating on the stock in a report on Thursday, April 17th. Raymond James reaffirmed an “outperform” rating and issued a $120.00 price target (down previously from $145.00) on shares of Revvity in a report on Tuesday. The Goldman Sachs Group dropped their price objective on shares of Revvity from $140.00 to $125.00 and set a “buy” rating on the stock in a report on Tuesday. Barclays cut their price objective on Revvity from $140.00 to $110.00 and set an “overweight” rating on the stock in a report on Thursday, April 10th. Finally, Robert W. Baird dropped their target price on Revvity from $127.00 to $125.00 and set an “outperform” rating on the stock in a research report on Tuesday. Four analysts have rated the stock with a hold rating, nine have assigned a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average price target of $126.46.

Revvity Stock Performance

NYSE:RVTY opened at $94.75 on Wednesday. The stock has a market capitalization of $11.38 billion, a PE ratio of 42.87, a P/E/G ratio of 3.82 and a beta of 1.07. The company has a fifty day moving average of $104.08 and a two-hundred day moving average of $112.67. The company has a debt-to-equity ratio of 0.41, a quick ratio of 3.03 and a current ratio of 3.60. Revvity has a fifty-two week low of $88.53 and a fifty-two week high of $129.50.

Revvity (NYSE:RVTY) last issued its quarterly earnings results on Monday, April 28th. The company reported $1.01 EPS for the quarter, topping the consensus estimate of $0.96 by $0.05. Revvity had a return on equity of 7.68% and a net margin of 9.81%. The firm had revenue of $664.76 million during the quarter, compared to analysts’ expectations of $662.30 million. During the same period in the previous year, the business earned $0.98 earnings per share. The firm’s revenue for the quarter was up 2.3% on a year-over-year basis. As a group, research analysts forecast that Revvity will post 4.94 earnings per share for the current fiscal year.

Revvity Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Friday, August 8th. Shareholders of record on Friday, July 18th will be paid a $0.07 dividend. This represents a $0.28 dividend on an annualized basis and a yield of 0.30%. The ex-dividend date is Friday, July 18th. Revvity’s dividend payout ratio (DPR) is 12.67%.

Insider Activity

In other news, insider Joel S. Goldberg sold 15,170 shares of the firm’s stock in a transaction that occurred on Thursday, January 30th. The shares were sold at an average price of $126.73, for a total transaction of $1,922,494.10. Following the completion of the sale, the insider now owns 33,400 shares in the company, valued at $4,232,782. This trade represents a 31.23 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Company insiders own 0.68% of the company’s stock.

About Revvity

Revvity, Inc provides health sciences solutions, technologies, and services in the Americas, Europe, and Asia, and internationally. The Life Sciences segment provides instruments, reagents, informatics, software, subscriptions, detection, imaging technologies, warranties, training, and services. Its Diagnostics segment provides instruments, reagents, assay platforms, and software products for the early detection of genetic disorders, such as pregnancy and early childhood, as well as infectious disease testing in the diagnostics market.